

**Global Health Clinics Ltd.**  
400-837 West Hastings Street  
Vancouver, BC V6C 3N6  
Tel: 1.855.537.6272

**NOT FOR DISSEMINATION IN THE UNITED STATES**

---

**NEWS RELEASE**

---

**GLOBAL HEALTH ANNOUNCES MANAGEMENT CHANGES AT WONDER  
SCIENTIFIC, INCLUDING THE APPOINTMENT OF SENIOR PHRAMA EXEC DR.  
BRIAN JAHNS**

**Vancouver, BC, April 29– Global Health Clinics Ltd.** (CSE: MJRX / FRANKFURT: L002) (“**Global Health**” or the “**Company**”) announces management changes at its Wonder Scientific Division. Wonder Scientific was acquired by the Company on January 20, 2021 (see January 20, 2021 news release), and is focused on sourcing and securing access to federally licensed work & bench space required for formulation and manufacturing work in the B2B sales channels of the active pharmaceutical ingredients (API) industry, including psilocybin. In order to align the strategic goals of the Company and Wonder Scientific in the biopharmaceutical industry, the Company has made significant management changes. Tegan Adams, a co-founder of Wonder Scientific, is no longer with the Company or Wonder Scientific. Istok Nahtigal and Angela Caruk, former consultants of Wonder Scientific, are also no longer consulting for Wonder Scientific.

The Company continues in discussion with consultant Dr. Andrew Riseman, a Wonder Scientific consultant, with a view to continuing to advance the ongoing relationship between the parties towards the development of research on optimizing production for psilocybin mushrooms, mycelium productions and the creation of a genetics library. To date, Dr. Riseman has curated a library of 18 genotypes of *Psilocybe* spore cultures on behalf of Wonder Scientific, and has applied for a controlled substances license from Health Canada under which his work with Wonder Scientific will proceed. Dr. Riseman’s current consulting agreement with Wonder Scientific will expire at the end of May 2021.

The Company is pleased to announce that its Wonder Scientific division will now be led by Dr. Brian Jahns. Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business development of Wonder Scientific, including its key corporate objectives of sourcing and securing access to federally licensed work and bench space required for formulation and manufacturing work in the business-to-business sales channels of the industry. Importantly, Dr. Jahns will focus on the custom creation of naturally derived APIs to supply the growing global clinical and commercial demand for psychedelics.

“I believe strongly in the potential of psychedelic therapeutics, and I’m excited by the prospect of working with Jay and his team,” said Dr. Jahns regarding his new role with Wonder Scientific.

Dr. Jahns has held senior leadership roles in the biopharmaceutical industry, including ZYUS, Trillium Therapeutics and Roche Canada, and has been deeply involved in the successful launch and growth of several successful compounds, including antiviral agents, transplant drugs and anticancer biologics, and developing targeted therapies for previously untreated diseases. Dr. Jahns has led preparations for commercialization, led efforts to procure commercial-scale manufacturing and led business partnering

activities for several compounds. He is currently chief business officer at Enttheon Biomedical (CSE: ENBI), and is a licensed pharmacist, Doctor of Pharmacy and clinical toxicologist. Dr. Jahns also advises the University of Toronto MaRS Discovery District, mentoring start-up biopharma and diagnostic companies, and has been published in numerous scientific journals.

“An executive of Dr. Jahns' acumen brings invaluable expertise to Wonder Scientific as we work towards our goal of developing naturally derived API's,” said chief executive officer Jay Dhaliwal.

The Company continues to seek talented team members who are aligned with the Company's vision of Wonder Scientific becoming as a supplier of clean-start *Psilocybe* genetics to the psychedelics research and novel drug development industry. If the Company is unable to obtain this expertise, it could delay the development of the Company's operations and could have a material adverse effect on the business of the Company. The Company will provide further updates on its advancements at Wonder Scientific as this business continues to move forward.

## **ON BEHALF OF THE BOARD OF DIRECTORS**

### **GLOBAL HEALTH CLINICS LTD.**

Jatinder Dhaliwal  
Chief Executive Officer

For further information, readers are encouraged to contact Jatinder Dhaliwal, Chief Executive Officer, at 1.855.537.6272

*Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

### **Cautionary Note Regarding Forward-Looking Information**

*Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation that is based on expectations, estimates and projections as at the date of this news release. “Forward-looking information” in this news release includes information about the intentions, plans and future actions of the Company and Wonder Scientific. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainty therein. The Company provides forward looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*

